Are you over 18 and want to see adult content?
More Annotations
Trends Magazines - Śledzimy trendy w motoryzacji - BMW, VW, reszta świata. Trends are Your Friends!
Are you over 18 and want to see adult content?
Fietstours & verhuur in 150 wereldsteden: NL helpdesk & gids - Baja Bikes
Are you over 18 and want to see adult content?
Wedding Magician & Professional Close-Up Magician, Corporate Events
Are you over 18 and want to see adult content?
Hochzeitskleider 2015
Are you over 18 and want to see adult content?
Офисные перегородки в Санкт-Петербурге | Бесплатный расчет стоимости
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of transform.now.sh
Are you over 18 and want to see adult content?
A complete backup of universomaquiagem.com.br
Are you over 18 and want to see adult content?
A complete backup of elinformador.com.ve
Are you over 18 and want to see adult content?
A complete backup of formation-logiciel-libre.com
Are you over 18 and want to see adult content?
A complete backup of sjh-health.com.tw
Are you over 18 and want to see adult content?
A complete backup of tabuademares.com
Are you over 18 and want to see adult content?
Text
PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved. EMA ACCEPTS ASTELLAS/SEAGEN’S ENFORTUMAB VEDOTIN FOR The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Astellas and Seagen’s enfortumab vedotin. Astellas/Seagen’s MAA is seeking authorisation of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial (bladder) cancer, who have received a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy in PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT 17th April 2018. by. Rohit Patni. This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many asPHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. 15 YEARS OF BIOSIMILAR ACCESS IN EUROPE In Europe, biosimilars have now captured 10% of the total biologics market value, most of that (7%) in the past five years. By volume, the amount is substantially higher, reflecting the steadily increasing level of savings due to growing biosimilar competition and penetration. 4. Today, more than 60 biosimilars have been approved foruse in the
ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved. EMA ACCEPTS ASTELLAS/SEAGEN’S ENFORTUMAB VEDOTIN FOR The European Medicines Agency (EMA) has accepted a marketing authorisation application (MAA) for Astellas and Seagen’s enfortumab vedotin. Astellas/Seagen’s MAA is seeking authorisation of enfortumab vedotin for the treatment of adult patients with locally advanced or metastatic urothelial (bladder) cancer, who have received a PD-1 or PD-L1 inhibitor and a platinum-based chemotherapy in PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT 17th April 2018. by. Rohit Patni. This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as NOVARTIS ORAL THERAPY IPTACOPAN SHOWS PROMISE IN PNH 1 day ago · Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The data, presented at the Annual Congress ofthe
PATIENT PARTNERSHIP INDEX 2021 Celebrating and showcasing the top examples of partnerships between pharmaceutical companies and patient groups, the Patient Partnership Index 2021 results have been announced – with three companies awarded GOLD for their partnership work NEW HYBRID HEALTHCARE AGENCY STIRRED LAUNCHES 1 day ago · Stirred – a new hybrid healthcare agency – has been launched this week by former senior Pegasus colleagues Jo Spadaccino and Stuart Hehir. Between them, Spadaccino and Hehir have over 40 years’ experience in marketing and communications, having been part of the shareholding team that grew SMC BACKS FIVE NEW MEDICINES FOR NHS USE Most read articles Novartis reports 'clinically relevant' survival data for Lutathera Lynparza shows promise in preventing cancer recurrence GSK’s PD-1 inhibitor Jemperli approved in the UK PHARMA R&D: 2021 AND BEYOND Pharma R&D: 2021 and beyond. 4th February 2021. by. Naomi Ikeda. The pharmaceutical sector emerges into 2021 with exciting prospects. The race for a COVID-19 vaccine has stimulated innovation across the industry, but the sector has been building momentum for years. Prior to the current pandemic, the UK health and pharma industry was growingat
MODUS THERAPEUTICS PARTNERS WITH IMPERIAL COLLEGE LONDON 1 day ago · Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria. The research collaboration will be undertaken by a team led by ASTELLAS’ XTANDI BAGS NICE APPROVAL IN PROSTATE CANCER Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The positive decision is supported by data from the Phase III ARCHES trial, which showed Xtandi MHRA APPROVES VENCLYXTO FOR NEWLY DIAGNOSED AML 1 day ago · The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML). The MHRA has cleared Venclyxto (venetoclax) in combination with a NICE BROADENS ACCESS TO TREATMENTS FOR RHEUMATOID 1 day ago · The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis. The final appraisal document has recommended biologics, including anti-TNF blockers adalimumab and HOW TO START A CLINICAL RESEARCH SITE Clinical research provides financial and altruistic appeal: a successful site will conduct a diversity of studies with commensurate compensation. The data generated (from trials conducted) could possibly contribute to a regulatory agency submission for new drug approval. At the very least, a successful site will impact the drug development process.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and development IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Preclinical testing expected "within weeks" - News - PharmaTimes. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373deaths
COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcare systems, and this, therefore, represents a trend that must be opposed as strongly aspossible.
15 YEARS OF BIOSIMILAR ACCESS IN EUROPE COVID-19 has sent a shockwave through global healthcare systems, exposing the fragility built up over decades of increased demand and pricing pressure, and exacerbating the financial pressures on healthcare providers. While we have seen amazing work, with OPDIVO PLUS YERVOY MOVES CLOSER TO EU APPROVAL FOR DMMR Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as 350,000 Britons will receive such funding. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and development IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Preclinical testing expected "within weeks" - News - PharmaTimes. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373deaths
COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcare systems, and this, therefore, represents a trend that must be opposed as strongly aspossible.
15 YEARS OF BIOSIMILAR ACCESS IN EUROPE COVID-19 has sent a shockwave through global healthcare systems, exposing the fragility built up over decades of increased demand and pricing pressure, and exacerbating the financial pressures on healthcare providers. While we have seen amazing work, with OPDIVO PLUS YERVOY MOVES CLOSER TO EU APPROVAL FOR DMMR Bristol Myers Squibb’s (BMS) Opdivo plus Yervoy combination therapy has moved closer to EU approval for certain colorectal cancer patients, after scoring a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). The CHMP has recommended ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as 350,000 Britons will receive such funding. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved. PATIENT PARTNERSHIP INDEX 2021 1 day ago · Celebrating and showcasing the top examples of partnerships between pharmaceutical companies and patient groups, the Patient Partnership Index 2021 results have been announced – with three companies awarded GOLD for their partnership work NEW HYBRID HEALTHCARE AGENCY STIRRED LAUNCHES 22 hours ago · Stirred – a new hybrid healthcare agency – has been launched this week by former senior Pegasus colleagues Jo Spadaccino and Stuart Hehir. Between them, Spadaccino and Hehir have over 40 years’ experience in marketing and communications, having been part of the shareholding team that grew MHRA APPROVES VENCLYXTO FOR NEWLY DIAGNOSED AML 22 hours ago · The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved AbbVie and Roche’s Venclyxto for the treatment of newly diagnosed acute myeloid leukaemia (AML). The MHRA has cleared Venclyxto (venetoclax) in combination with a INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
NICE BROADENS ACCESS TO TREATMENTS FOR RHEUMATOID 22 hours ago · The National Institute for Health and Care Excellence (NICE) has published final draft guidance broadening access to several treatment for patients with moderate to severe rheumatoid arthritis. The final appraisal document has recommended biologics, including anti-TNF blockers adalimumab and ENTRY CLOSING NEXT FRIDAY FOR CROY 2021 Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18 th of June.. The 2021 competition is already shaping up to be another hotly contested event, and there is still time for clinical researchers from across the NOVARTIS ORAL THERAPY IPTACOPAN SHOWS PROMISE IN PNH 22 hours ago · Novartis has revealed new positive data for its investigational treatment iptacopan as a monotherapy treatment for patients with the rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH). The data, presented at the Annual Congress ofthe
SMC BACKS FIVE NEW MEDICINES FOR NHS USE Servier's Lonsurf and AstraZeneca's Calquence are among the positive decisions - News - PharmaTimes MODUS THERAPEUTICS PARTNERS WITH IMPERIAL COLLEGE LONDON 22 hours ago · Swedish biotech company Modus Therapeutics has announced a new collaboration with Imperial College London to research the effects of its drug sevuparin in patients with severe malaria. The research collaboration will be undertaken by a team led by HOW TO START A CLINICAL RESEARCH SITE Starting a clinical research site is an exciting opportunity for the ambitious research professional looking to progress from employee to site ownership, or the medical entrepreneur looking to expand a portfolio with a lucrative investment.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Preclinical testing expected "within weeks" - News - PharmaTimes. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373deaths
COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcare systems, and this, therefore, represents a trend that must be opposed as strongly aspossible.
COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and development INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
15 YEARS OF BIOSIMILAR ACCESS IN EUROPE COVID-19 has sent a shockwave through global healthcare systems, exposing the fragility built up over decades of increased demand and pricing pressure, and exacerbating the financial pressures on healthcare providers. While we have seen amazing work, with ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved. PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as 350,000 Britons will receive such funding.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Preclinical testing expected "within weeks" - News - PharmaTimes. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373deaths
COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcare systems, and this, therefore, represents a trend that must be opposed as strongly aspossible.
COMMUNICATIONS AWARDS Communications Awards. The PharmaTimes Communications Awards are back for 2021, giving the opportunity for communications professionals to demonstrate their leadership, creative, and teamwork skills in a variety of fun and engaging virtual challenges. CLINICAL RESEARCHER OF THE YEAR The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and development INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
15 YEARS OF BIOSIMILAR ACCESS IN EUROPE COVID-19 has sent a shockwave through global healthcare systems, exposing the fragility built up over decades of increased demand and pricing pressure, and exacerbating the financial pressures on healthcare providers. While we have seen amazing work, with ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. NOVARTIS UK ANNOUNCES FURTHER HRT PATCH STOCK ISSUES Novartis says it is expecting an additional temporary stock shortage of its HRT patch Estradot TTS-75, due to “manufacturing constraints”. Temporary stock shortages of around four weeks for Estradot TTS-75 and TTS 37.5 were first announced in January because of a printing issue, though were subsequently resolved. PATIENT HEALTH BUDGETS: A POSITIVE OR NEGATIVE DEVELOPMENT This week the NHS announced that it was going to be giving a greater number of patients their own budgets to source healthcare services. Building on the 23,000 people across the UK who already collect personal finances through the NHS’s Continuing Healthcare initiative, it’s reported that now as many as 350,000 Britons will receive such funding. PATIENT PARTNERSHIP INDEX 2021 9 hours ago · Celebrating and showcasing the top examples of partnerships between pharmaceutical companies and patient groups, the Patient Partnership Index 2021 results have been announced – with three companies awarded GOLD for their partnership work BAYER SUBSIDIARY DOSES FIRST PATIENT WITH PARKINSON’S 11 hours ago · German pharma company Bayer has announced that it has made progress in its ‘two-pronged’ approach to deliver cell and gene therapy candidates for the treatment of Parkinson’s disease. BlueRock Therapeutics, a wholly-owned subsidiary of Bayer, hasadministered the
CELL AND GENE THERAPY CATAPULT FORMS CONSORTIUM OF OVER 20 11 hours ago · The Cell and Gene Therapy (CGT) Catapult has announced the formation of a consortium of over 20 organisations, which will aim to accelerate technology development in cell and gene therapy manufacturing. The consortium consists of pharmaceutical companies, technology providers, therapy developers and TICKETS NOW ON SALE FOR INTCR 2021 Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards. Despite the turbulent year, the competition has once again seen great entry numbers across all of the hotly contested categories – the finalists now all eagerly await their chance to go for gold at the virtualfinals day.
ASTELLAS’ XTANDI BAGS NICE APPROVAL IN PROSTATE CANCER 11 hours ago · Astellas’ oral treatment Xtandi has received approval from the National Institute for Health and Care Excellence (NICE) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The positive decision is supported by data from the Phase III ARCHES trial, which showed Xtandi AMICUS' POMPE DISEASE THERAPY JOINS EARLY ACCESS SCHEME 1 day ago · Patients with late-stage Pompe disease who are failing to respond to enzyme replacement therapy will now have early access to an alternative treatment option, after Amicus Therapeutics' cipaglucosidase alfa with miglustat was approved for the UK's Early Access to Medicine Scheme (EAMS). OPDIVO COMBOS SHOW OS BENEFIT IN ADVANCED OESOPHAGEAL 11 hours ago · Bristol Myers Squibb’s (BMS) immunotherapy Opdivo, when administered alongside chemotherapy or Yervoy, demonstrated significant overall survival (OS) benefit compared to chemotherapy alone in advanced/metastatic oesophageal cancer patients. Interim analysis data from the Phase III CheckMate-648 GOV'T ANNOUNCES DELAY TO GP DATA EXTRACTION SCHEME 1 day ago · The government has announced a two-month delay to its planned GP data extraction programme, originally planned for early July. Announcing the delay in the House of Commons, health minister Jo Churchill said roll out of the new system, the General Practice Data for Planning and Research, has been pushed back to September, essentially to allow for patients and doctors toCONNECTING THE DOTS
The pharmaceutical industry, with the clinical trial process at its core, operates on a truly global scale, conducting studies to determine the safety and efficacy of therapies and vaccines, fundamental to the advancement of human health. For those involved in the facilitation of clinical trials HOW TO START A CLINICAL RESEARCH SITE Starting a clinical research site is an exciting opportunity for the ambitious research professional looking to progress from employee to site ownership, or the medical entrepreneur looking to expand a portfolio with a lucrative investment.PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
REAL-WORLD DATA SUGGESTS SPUTNIK V VACCINE IS 97.6% Lucy Parsons. New real-world data has suggested that Russia’s Sputnik V vaccine is 97.6% effective against COVID-19, the Gamaleya Institute and the Russian Direct Investment Fund (RDIF) announced yesterday. The new efficacy rate is based on the analysis of data from 3.8 million Russians vaccinated with both components of Sputnik V from ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. AZ BAGS POSITIVE RESULTS IN INVESTIGATIONAL LUPUS DRUG AZ bags positive results in investigational Lupus drug trial. 29th August 2019. by. Anna Smith. AstraZeneca has announced that its potential new systemic lupus erythematosus (SLE) medicine, anifrolumab, has met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction indisease activity.
PFIZER LAUNCHES CHRONIC PAIN CAMPAIGN 29th January 2013. by. Selina McKee. Drug giant Pfizer has this morning launched a new campaign designed to get patients suffering from chronic pain talking to each other, to improve communication and accelerate diagnosis of the condition. The Pain Exchange is an online forum designed to promote conversation about pain between patients tohelp
FAILURE TO LAUNCH
A new report delves into why so many pharma brands struggle to launch and what can be done about it There has never been a more challenging time for product launch in the pharmaceutical industry, conclude the authors of a new report from management consultants Eden McCallum.“Approvals are
PHARMATIMES
The PharmaTimes portfolio includes the well-respected monthly PharmaTimes Magazine; three news elert services; business forums, where thought-leaders meet to discuss the issues of the day; and a series of awards that recognise, reward and celebrate excellence. IMOPHORON DEVELOPS COVID-19 VACCINE CANDIDATES Imophoron develops COVID-19 vaccine candidates. As of this morning – Tuesday April 7 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 51,608 with 5,373 deaths. UK biotech Imophoron says it has produced multiple COVID-19 vaccine candidates based on its novel vaccine platform ADDomer. COVID AND THE GROWING THREAT OF COUNTERFEIT MEDICINES COVID and the growing threat of counterfeit medicines. 29th April 2021. by. Mike Seed. Counterfeiting has always been one of the most serious and insidious threats faced by the pharmaceutical industry. Falsified or substandard drugs can cause significant damage in terms of consumer health, economic impact and public trust in healthcaresystems
CLINICAL RESEARCHER OF THE YEAR Clinical Researcher of the Year - The Americas 2021. The PharmaTimes Clinical Researcher of the Year – The Americas competition is back again for 2021, designed to uncover the exceptional talent of clinical researchers across the Americas. Over the past decade this challenge has gained a strong reputation of being a valuable learning and INTERNATIONAL CLINICAL RESEARCHER OF THE YEAR International Clinical Researcher of the Year 2021. Raising standards in clinical research for over 20 years. After an innovative 2020 competition which saw our finalists compete virtually, the 2021 competition has launched, offering once again a renowned challenge designed to test, develop, and reward clinical researchers working allover the globe.
REAL-WORLD DATA SUGGESTS SPUTNIK V VACCINE IS 97.6% Lucy Parsons. New real-world data has suggested that Russia’s Sputnik V vaccine is 97.6% effective against COVID-19, the Gamaleya Institute and the Russian Direct Investment Fund (RDIF) announced yesterday. The new efficacy rate is based on the analysis of data from 3.8 million Russians vaccinated with both components of Sputnik V from ANTIBIOTIC RESEARCH UK CALLS FOR CLEAR GUIDANCE ON THE USE Antibiotic Research UK (ANTRUK) has urged the UK government to provide clarity on whether people receiving antibiotics can also receive a COVID-19 vaccination. AZ BAGS POSITIVE RESULTS IN INVESTIGATIONAL LUPUS DRUG AZ bags positive results in investigational Lupus drug trial. 29th August 2019. by. Anna Smith. AstraZeneca has announced that its potential new systemic lupus erythematosus (SLE) medicine, anifrolumab, has met its primary endpoint, achieving a statistically-significant and clinically-meaningful reduction indisease activity.
PFIZER LAUNCHES CHRONIC PAIN CAMPAIGN 29th January 2013. by. Selina McKee. Drug giant Pfizer has this morning launched a new campaign designed to get patients suffering from chronic pain talking to each other, to improve communication and accelerate diagnosis of the condition. The Pain Exchange is an online forum designed to promote conversation about pain between patients tohelp
FAILURE TO LAUNCH
A new report delves into why so many pharma brands struggle to launch and what can be done about it There has never been a more challenging time for product launch in the pharmaceutical industry, conclude the authors of a new report from management consultants Eden McCallum.“Approvals are
TICKETS NOW ON SALE FOR INTCR 2021 1 day ago · Individual tickets or tables are now available for the 2021 International Clinical Researcher of the Year awards. Despite the turbulent year, the competition has once again seen great entry numbers across all of the hotly contested categories – the finalists now all eagerly await their chance to go for gold at the virtualfinals day.
ENTRY CLOSING NEXT FRIDAY FOR CROY 2021 18 hours ago · Entry for the 2021 Clinical Researcher of the Year – The Americas will be closing next Friday the 18 th of June.. The 2021 competition is already shaping up to be another hotly contested event, and there is still time for clinical researchers from acrossthe
AMGEN’S KRAS INHIBITOR LUMAKRAS SCORES POSITIVE OVERALL 1 day ago · Amgen has presented new data on overall survival (OS) for its KRAS inhibitor Lumakras in previously treated non-small cell lung cancer (NSCLC) at the 2021 American Society of Clinical Oncology (ASCO) annual meeting. The Phase II results of the CodeBreaK SMC BACKS FIVE NEW MEDICINES FOR NHS USE 17 hours ago · Most read articles Janssen’s myeloma CAR T therapy cilta-cel demonstrates ‘sustained efficacy’ Novartis reports 'clinically relevant' survival data for Lutathera MHRA AUTHORISES PFIZER/BIONTECH’S COVID-19 VACCINE FOR 12 1 day ago · The UK Medicines and Healthcare products Regulatory Agency (MHRA) has extended the authorisation of Pfizer/BioNTech’s COVID-19 vaccine for use in children aged 12 to 15 years old. On Friday, the MHRA announced that it had concluded that the NEW RESEARCH IDENTIFIES SINGLE BIOMARKER THAT CAN INDICATE 17 hours ago · New research has identified a single biomarker that can be used to accurately identify underlying neurodegeneration among people with cognitive issues. The new study, led by King’s College London, examined samples from 3138 samples, including people GSK’S PD-1 INHIBITOR JEMPERLI APPROVED IN THE UK 1 day ago · GlaxoSmithKline’s (GSK) PD-1 inhibitor Jemperli has been authorised by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of recurrent or advanced endometrial cancer. Specifically, Jemperli (dostarlimab) has been granted a conditional marketing authorisation for IKSUDA THERAPEUTICS RAISES $47M TO PROGRESS ADC PIPELINE 1 day ago · Newcastle, UK-headquartered Iksuda Therapeutics has announced the closing of a $47m (£34m) financing round, with the funds to be used to support the advancement of its lead antibody drug conjugate (ADC) assets. This includes the company’s lead BIOGEN, EISAI’S ALZHEIMER’S DRUG ADUCANUMAB MAKES HISTORY 17 hours ago · The US Food and Drug Administration (FDA) has granted Biogen and Eisai’s aducanumab and accelerated approval, making it the first new treatment approved for Alzheimer's disease in over a decade. The accelerated approval for aducanumab – now known asAduhelm –
NICE RECOMMENDS TECENTRIQ FOR FIRST-LINE NSCLC 17 hours ago · The UK National Institute for Health and Care Excellence (NICE) has recommended Roche’s Tecentriq (atezolizumab) monotherapy for untreated metastatic non-small cell lung cancer (NSCLC). Tecentriq (atezolizumab) is indicated for adults with metastatic NSCLC if their tumours have PD-L1 expression on Our website uses cookies to improve your experience. You can change your cookie settings at any time, otherwise we'll assume you're OK tocontinue Learn more
Remove this message
* Subscribe
* Advertise
* About us
__ __
__
__
Go
* Magazine
* Web Exclusives
* News
* Competitions
* Appointments
* Jobs
* Business Insights
* Webinars
* Thought Leadership__
__
*
* Magazine
* Overview
* Latest Issue
* Business Insights
* Subscribe
* Have your Say
* Media information
* Magazine Archive
* Web Exclusives
*
* News
* News
* Free news subscriptions* Free RSS Feed
*
* Competitions
* Overview
*
* Marketer
* Marketer of the year* Overview
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* Communications Team * Communications Team of the year* Overview
* Where & When
* Enter
* Nominate
* Categories
* Latest News
* How the Competition Works* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* International Clinical Researcher * International Clinical Researcher of the Year* Overview
* 2020 Winners
* Finalists 2020
* Where & When
* Categories
* How It Works
* Enter
* Nominate
* Executive Steering Group* Alumni
* Gallery
* Videos
* Testimonials
* Sponsorship Opportunities* Sponsors
* Latest News
* Terms & Conditions* Privacy Policy
* Contact Us
*
* Clinical Researcher - The Americas * Clinical Researcher of the Year - The Americas* Overview
* How the competition works* Categories
* Enter
* Nominate
* Executive Steering Group* Alumni
* Winners 2020
* Gallery
* Videos
* Testimonials
* Sponsorship Opportunities* Sponsors
* Latest News
* Terms & Conditions* Privacy Policy
* Contact Us
*
* Sales Awards
* Sales Awards
* Overview
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Gallery
* Alumni
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
*
* Medical & Scientific Excellence Awards * Medical & Scientific Excellence Awards* Overview
* 2019 Results
* Book Tickets
* Where & When
* Enter
* Nominate
* Latest News
* How the Competition Works* Categories
* Testimonials
* Alumni
* Gallery
* Sponsors
* Steering Group
* Sponsorship Opportunities* Become a Judge
* Contact Us
* Appointments
* Jobs
* Business Insights
* Thought Leadership* Subscribe
* Advertise
* About us
COVID-19: KEEP UP TO DATE WITH THE LATEST PHARMACEUTICAL AND HEALTHCARE NEWS AS THE PANDEMIC EVOLVES*
STAR TRACKING ACROSS THE PHARMAVERSE While the COVID-19 menace has wreaked havoc across global industries, pharma’s commitment to logistical zeal has provided a supersonic slipstream to optimal performance, not to mention salvation for millions of patients*
DATA – THE KEY TO RESHAPING PATIENT PATHWAYS Oli Hudson, of Wilmington Healthcare, explains why pharma needs to put data at the heart of its bid to support the NHS Reset*
ARTIFICIAL INVENTORS The question of artificial intelligence as an inventor – and what it means for drug discoveryNEWS
View all
COLCHICINE ADDED TO UK’S COVID-19 ‘RECOVERY’ TRIAL Commonly used anti-inflammatory drug added to list of potentialtreatments
30th November 2020
RESEARCHERS WARN PANDEMIC COULD DELAY CANCER ADVANCES ‘BY ALMOST AYEAR’
Survey included input from scientists at The Institute of CancerResearch, London
30th November 2020
DUPIXENT APPROVED IN EU FOR ATOPIC DERMATITIS IN CHILDREN First biologic to be approved for children aged six to 11 years withcondition
30th November 2020
UK SECURES ANOTHER TWO MILLION DOSES OF MODERNA’S COVID-19 VACCINE New agreement takes supply up to seven million doses in total30th November 2020
SYMKEVI/KALYDECO CLEARED FOR USE IN YOUNG CF PATIENTS The combination is the first available to treat the underlying cause of CF in this patient group.27th November 2020
TOP TRENDING
*
NHS TO TRIAL INNOVATIVE CANCER BLOOD TEST*
PFIZER TO BUILD R&D FACILITY IN WUHAN, CHINA*
SANOFI’S MENINGOCOCCAL VACCINE WINS EU APPROVAL*
AMAZON LAUNCHES ONLINE PHARMACY IN THE US*
GSK LAUNCHES LATE-STAGE STUDY OF RSV VACCINE IN PREGNANT MOTHERS*
NICE BACKS USE OF NEW TREATMENT FOR MULTIPLE MYELOMAWEB EXCLUSIVES
View all
NOW OR NEVER
The security of our medicines supply chain mattersA PRIME TARGET
How can pharma protect itself from cyber criminals? PHARMACOVIGILANCE IN A PANDEMIC WORLD Infusing automation into pharmacovigilance for COVID-19 treatments CREATIVE MED AFFAIRS AND BRIDGING THE HEALTHCARE GAP Med affairs will need to take an increasingly significant role when it comes to engaging with patients and HCPs to unlock the full potential of healthcare, and creativity is the keyMAGAZINE
View more from the latest edition PATIENT FILES: SPINAL MUSCULAR ATROPHY (SMA) Cheryl Yoder shares her family’s experiences with this rare, geneticdisorder
BRANCHING OUT
Pharma companies have improved how they engage with healthcare providers during COVID-19, says Accenture’s Brad Michel DECENTRALISING RESEARCH Revolutionising clinical trials with wearables and digital endpoints REINVENTING PATIENT ENGAGEMENT Lessons from the Patient Partnership Index conference ARTIFICIAL INVENTORS The question of artificial intelligence as an inventor – and what it means for drug discovery KEEPING TRIAL DATA ALIVE Insight into the conduct of clinical trials and managing data amid thepandemic
MAINTAINING CROSS-BORDER MEDICINES SUPPLY Updated guidelines from the European Medicines Agency for pharmaceuticals marketing authorisation holders offer new clarity on what they must do to maintain continuity of supply of UK-registered products in Europe once the Brexit transition period ends. RETHINKING CANCER DETECTION If we are to truly beat cancer, we need to pay as much attention to detecting it as we do treating itTHOUGHT LEADERSHIP
View all
LET’S HAVE A CHAT: WHY BRISTOL MYERS SQUIBB IS TACKLING LONELINESS Keeping the spirit of connection alive through the Have a Chatcampaign
THE CONCORDANCE CONUNDRUM – THE TECH DIVIDE Consultations in a virtual world THE CONCORDANCE CONUNDRUM: THE VALUE OF IMPROVING PATIENT EXPERIENCE The art of active listening NEW PRODUCT VS ESTABLISHED BRAND INVESTMENT? A trade-off you no longer have to make in this changing worldWEBINARS
View all
DESIGNING PHARMA ORGANISATIONS FOR SUCCESS Across all industries, people are changing the ways they engage with products, services, and brands. View more... _Wednesday, 28 September 2016 - 11:00 am_George Underwood
FREE - Listen again now - | VIEW NOW Get the latest pharma news delivered to your inbox A valid email address is required.Subscribe for free
LATEST JOBS
View all
ACCOUNT MANAGER- ADULT NUTRITION -YORKSHIRE/TEESSIDE/N LINCS Competitive Salary and Bonus INTERNATIONAL EVENTS MANAGER - NEUROLOGY - BERKSHIRE Competitive Salary and Bonus SENIOR SCIENTIFIC ADVISOR - MEDICAL AESTHETICS Competitive Salary and BonusMSL LEAD
Negotiable
BRAND MANAGER - GASTROENTEROLOGY - EAST MIDLANDS Competitive Salary and Bonus MARKET ACCESS HEAD - CARDIAC DEVICES - NORTH UK Competitive Salary and Bonus What job are you looking for? This field is required.Find jobs
SOCIAL MEDIA
LATEST VIDEOS
Marketer, Communications Team of the year and Sales awardsLATEST ON INSTAGRAM
Visit PharmaTimes Media Ltd's profile on Instagram.LATEST TWEETS
DOWNLOAD OUR APPS
Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app. Go to the App Store or Google Play and search for 'PharmaTimes' to download our free app.CONTENT
* News
* Magazine
* Advertise
* Contact
* Competitions
CONNECT
* __ RSS
* __ Instagram
* __ Vine
* __ Pinterest
* __ Twitter
* __ Linkedin
LEGAL
* Privacy policy
* Terms and Conditions* Editorial policy
* Cookies
* RSS - feed subscriptions Copyright PharmaTimes Media Limited 2020Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0